A novel signal directed tissue microdissection method is provided that forms the foundation for an entire multistep panomic (proteomic/genomic) process to inform and ascertain an optimal individualized cancer treatment strategy. Patient tumor tissue is sectioned onto DIRECTOR slides and tumor cells are identified by an inclusion signal while unwanted cells such as normal stroma are identified by an exclusion signal, and whereby such signals are determined by a clinically-trained histologist/pathologist, the presence or absence of immunohistochemical staining, or a combination of both. A liquefied biochemical lysate is prepared from the tumor cells whereby genomics and proteomics assays are performed to inform optimal cancer treatment strategies for the patient that includes chemotherapy agents, targeted therapeutic agents, cancer vaccines, and immunomodulatory agents individually or in combination.
